Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2025Open Access

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

SMStefano MolicaDADavid Allsup

Discussion

Loading...

Member takes

Overview

Phase 3 trial reveals pirtobrutinib's efficacy against resistance mutations in chronic lymphocytic leukaemia, suggesting new treatment pathways.

Key Points

  • Pirtobrutinib achieved an overall response rate of 62% in heavily pretreated CLL patients, enhancing treatment options.
  • The median progression-free survival was approximately 20 months, indicating effectiveness in overcoming resistance mechanisms.
  • Noncovalent BTK inhibitors may improve long-term disease control, actively addressing limitations seen with traditional covalent BTK inhibitors.
  • Molecular analyses show that baseline genetic features notably influence treatment outcomes and response durability.

Cite This Study

Molica et al. (2025) studied this question.

synapsesocial.com/papers/68af4093cf1dd9ea359ec6f6https://doi.org/10.20944/preprints202508.1373.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy2025 · 4 citations
  2. 2Pirtobrutinib, a non-covalent BTK inhibitor, enhances T-cell anti-tumor immunity in chronic lymphocytic leukemia (CLL)2025
  3. 3New BTK Inhibitors May Combat Resistance in CLL2025
  4. 4Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study2025 · 4 citations
  5. 5Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor2025 · 2 citations